Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MLNR | O43193 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12100332 | 1.00 | CYP2D6 (0.34) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL1036841 | 1.00 | CYP2D6 (0.34) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL1110628 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL1110703 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL1110677 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| Hydrochloric Acid SCHEMBL1032821 | 0.97 | KDM4E (0.37) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL325293 | 0.92 | — | — | |
| SCHEMBL894123 | 0.92 | — | — | |
| SCHEMBL232815 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL17202018 | 0.90 | KDM4E (0.42) | CYP2D6CYP1A2KDM4ENPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| EP-3873900-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112969700-B | Imidazopyridine derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024042316-A1 | PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER | REDX PHARMA PLC. (GB) | 2024-02-29 | — | — | WO | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4038060-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-5605926-A | PROPHYLAXIS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-25 | — | — | US | disclosed |
| EP-0744954-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | Bayer Corporation (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0694076-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | Bayer Corporation (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0694076-A4 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | BAYER AG (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5430151-A | Treatment of aids, pneumonia, caprine arthritis encephalitis, leukemia and immmunodeficiency | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-04 | — | — | US | disclosed |
| WO-1995013084-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | MILES INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994013319-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | MILES INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0528242-A2 | Trifluoromethyl containing pseudopeptides | BAYER AG (DE) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | CYP2D6 4482/4885CYP1A2 4157/4885KDM4E 1212/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | CYP2D6 4/4885CYP1A2 13/4885KDM4E 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.